Companies · FMC
FMC Corporation
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Jul 30, 2026
FMC Q2 2026: Revenue down 17% on volume and price collapse; Tessenderlo equity investment and asset monetization race to stabilize $4.3B debt load
FMC's Q2 2026 results confirm an accelerating demand and pricing deterioration across all four geographies, with organic revenue down 22% in the quarter as grower margin pressure suppresses input purchases and generic competition erodes both legacy portfolio and Rynaxypyr active pricing. The company has pivoted to an emergency balance sheet stabilization program — simultaneously monetizing the rimisoxafen IP via a $200 million Corteva prepayment, divesting the India commercial business for $252 million, selling its Newark R&D real estate for approximately $114 million, and accepting a $400 million strategic minority equity investment from Belgium's Tessenderlo Group — all proceeds earmarked for debt reduction against a $4.28 billion total debt position. Project Foundation restructuring charges have been revised upward to $700–775 million total, with targeted annual run-rate savings now raised to $200 million by end-2027, but the timeline and size of the cost program underscores the depth of the structural reset underway.
Tone: defensiveRevenue
$3.5B
FMC 10-K · FY 2025
Employees
5,500
Revenue FY2024
$4.2B
Headquarters
Philadelphia, PA
Profile
FMC 10-K Item 1 · Feb 27, 2026FMC Corporation is a global agricultural sciences company that develops, markets, and sells crop protection chemicals — insecticides, herbicides, and fungicides — as well as biologicals, crop nutrition, and seed treatment products. The company operates as a single business segment and serves farmers across all major geographic regions. FMC's strategy centers on proprietary active ingredients, a pipeline of novel modes of action, and ongoing cost restructuring to defend margins against generic competition.
Read filing description ↓ Collapse description ↑
FMC Corporation is a global agricultural sciences company dedicated to providing farmers with innovative solutions that increase the productivity and resilience of their land. We operate in a single distinct business segment. We develop, market and sell all three major classes of crop protection chemicals (insecticides, herbicides and fungicides) as well as biologicals, crop nutrition, and seed treatment products, which we group as plant health. FMC's innovative crop protection solutions help growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC is committed to discovering new insecticide, herbicide, and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. We are a tier-one leader in the agrochemicals/crop protection market. Our position in the market is driven by our technology and innovation, as well as our geographic balance and crop diversity. Our portfolio is comprised of three major pesticide categories: insecticides, herbicides and fungicides. The majority of our product lines consist of insecticides and herbicides, and we have a growing portfolio of fungicides mainly used in high value crop segments. We are also investing in our Plant Health program which includes biologicals, crop nutrition, and seed treatment products. Biological technologies offer excellent sustainability profiles and serve as strong complements to our synthetic products. Our biologicals feature attributes such as high stability, long shelf life, low use rates and compatibility with other chemistries.
Primary products
- Insecticides
- Herbicides
- Fungicides
- Biologicals
- Crop nutrition
- Seed treatment products
Business segments
End markets
Geographies
Named customers
Named competitors
“We are a tier-one leader in the agrochemicals/crop protection market. Our position in the market is driven by our technology and innovation, as well as our geographic balance and crop diversity.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Revenue decreased approximately 18 percent in 2025 versus 2024, primarily driven by $422 million in revenue charges from one-time commercial actions taken to prepare the India commercial business for sale; excluding those actions, revenue declined approximately 8 percent due to a 6 percent price decline and competitive pressure on core portfolio products.
The rest of FMC is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.